


Dazmegrel

Chemical Properties

CAS No. :	76894-77-4
Formula:	C ₁₆ H ₁₇ N ₃ O ₂
Molecular Weight:	283.33
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Dazmegrel (UK 38,485) is a potent and specific thromboxane A ₂ (TXA ₂) synthase inhibitor for the prevention of increased whole platelet aggregation in normal pregnancy.
Targets(IC ₅₀)	PPAR, Prostaglandin Receptor

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.5295 mL	17.6473 mL	35.2945 mL
5 mM	0.7059 mL	3.5295 mL	7.0589 mL
10 mM	0.3529 mL	1.7647 mL	3.5295 mL
50 mM	0.0706 mL	0.3529 mL	0.7059 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Langleben D, et al. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension. *Am Rev Respir Dis.* 1986 May;133(5):789-91.
- Lorenz RL, et al. Effects on prostanoid formation and pharmacokinetics of dazmegrel (UK-38,485), a novel thromboxane synthase inhibitor, in man. *Biochem Pharmacol.* 1986 Mar 1;35(5):761-6.
- Wang SL. [Effect of the thromboxane synthetase inhibitor dazmegrel (UK 38,485) on skin blood flow in deep partial thickness burns]. *Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi.* 1989 Sep;5(3):206-9, 239-40. Chinese.
- Bullock GR, et al. Effects of a combination of metoprolol and dazmegrel on myocardial infarct size in rats. *Br J Pharmacol.* 1985 Sep;86(1):235-40.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481